<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665392</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593027</org_study_id>
    <secondary_id>GERCOR-ECHO-07-1</secondary_id>
    <secondary_id>EUDRACT 2007-002116-25</secondary_id>
    <secondary_id>EU-20838</secondary_id>
    <secondary_id>MERCK-GERCOR-ECHO-07-1</secondary_id>
    <nct_id>NCT00665392</nct_id>
  </id_info>
  <brief_title>Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
      docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy) together with cetuximab may kill more tumor cells.

      PURPOSE: This phase II clinical trial is studying how well cetuximab given together with
      combination chemotherapy works in treating patients with stage III or stage IV oropharynx
      cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the complete clinical response rate at 3 months in patients with stage III
           or IV nonmetastatic squamous cell carcinoma of the oropharynx treated with cetuximab,
           docetaxel, cisplatin, and fluorouracil.

      Secondary

        -  To determine the rate of tumor response.

        -  To determine progression-free and overall survival.

        -  To determine the rate of complete pathological response.

        -  To assess the tolerability of this regimen in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15; docetaxel IV over 1 hour
      and cisplatin IV over 1 hour on day 1; and fluorouracil IV continuously on days 1-5.
      Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study therapy, patients are followed every 2 months for 1 year and every
      3 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical response rate at 3 months</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of response (partial and complete response and stable disease)</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>from inclusion to first disease progression with chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From inclusion to patient's decease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic response</measure>
    <time_frame>after surgery of the primary tumor</time_frame>
    <description>On primary tumor resected : measure of persistence or not of tumoral lesion, histological type, size and quality of the excision piece</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>until 1 month after the last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>75 mg/m², day 1. 3 cycles</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>75 mg/m² Day 1. 3 cycles</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>750 mg/m² day 1 to day 5. 3 cycles</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.</description>
    <arm_group_label>cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the oropharynx

               -  Stage III (T3 or T1-2, N1-2, M0) or nonmetastatic stage IV (T4 or T1-3, N3, M0)
                  disease

               -  Resectable disease

          -  Measurable or evaluable disease

          -  Tumor tissue available

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-1

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Creatinine &lt; 1.5 times upper limit of normal (ULN)

          -  Creatinine clearance ≥ 60 mL/min

          -  AST and ALT &lt; 5 times ULN

          -  Bilirubin &lt; 1.5 times ULN

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Affiliated with social security (including CMU)

        Exclusion criteria:

          -  Cardiovascular accident (myocardial infarction, cerebral vascular accident) within the
             past 6 months

          -  Serious and/or uncontrolled cardiac or respiratory disease (pulmonary fibrosis,
             interstitial pneumopathy)

          -  Other cancer within the past 5 years except for resected skin cancer, localized
             cutaneous or totally resected melanoma, or resected carcinoma in situ of the cervix

          -  Auditory condition precluding the use of cisplatin

          -  Contraindication due to psychological, social, or geographical reasons that may impede
             proper monitoring of treatment

          -  Persons under guardianship or trusteeship, or prisoners of law

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment, including chemotherapy or radiotherapy

          -  No concurrent phenytoin, live attenuated vaccines, or parenteral aminoglycosides
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Lacau Saint Guily, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Tenon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Simone Veil</name>
      <address>
        <city>Montmorency</city>
        <zip>95160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé St Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 21, 2016</submitted>
    <returned>February 10, 2017</returned>
    <submitted>February 13, 2017</submitted>
    <returned>March 30, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

